Huang Richard H, Hu Ke-Qin
Division of Gastroenterology and Hepatology, University of California, Irvine Medical Center, CA 92868, USA.
Int J Med Sci. 2006;3(2):63-8. doi: 10.7150/ijms.3.63. Epub 2006 Apr 1.
Hepatitis C virus (HCV) infection is a major worldwide public health concern. It is a common cause of chronic liver disease and hepatocellular carcinoma. HCV antibody and HCV RNA testing are available diagnostic studies that offer high degree of accuracy. Current standard therapy includes a combination of pegylated interferon and ribavirin. Response rate is approximately 40% for genotype 1 and 80% for genotypes 2 and 3, respectively. Successful treatment can stop the progression of chronic liver disease, reduce the need for liver transplantation, and possibly decrease the risk for Hepatocellular carcinoma (HCC). Evaluating for potential treatment candidacy is an important initial step in the management of chronic HCV infection as not all individuals may need or qualify for the treatment. Understanding the natural history, the different diagnostic modalities, the current therapeutic options and, the treatment response and adverse effect profiles can help the practitioners better manage chronic HCV infection.
丙型肝炎病毒(HCV)感染是全球主要的公共卫生问题。它是慢性肝病和肝细胞癌的常见病因。HCV抗体和HCV RNA检测是准确性很高的现有诊断研究。目前的标准疗法包括聚乙二醇化干扰素和利巴韦林联合使用。基因1型的应答率约为40%,基因2型和3型分别为80%。成功的治疗可以阻止慢性肝病的进展,减少肝移植需求,并可能降低肝细胞癌(HCC)风险。评估潜在的治疗候选资格是慢性HCV感染管理中的重要初始步骤,因为并非所有个体都需要或适合接受治疗。了解其自然史、不同的诊断方式、当前的治疗选择以及治疗反应和不良反应情况,有助于医生更好地管理慢性HCV感染。